Showing results (41-50 of 165) with videos related to
Sort By:
Pageof 17
Gynecologic Oncology|July 17, 2021
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal CancerFloor J Backes, Lai Wei, Min Chen, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2015
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic ChemotherapyCaroline C Billingsley, Samuel N Jacobson, Sarah M Crafton, et al.Journal of Minimally Invasive Gynecology|January 19, 2016
A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial CancerDavid E Cohn, Karina Castellon-Larios, Laura Huffman, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 15, 2011
The impact of body weight on ovarian cancer outcomesFloor J Backes, Christa I Nagel, Elizabeth Bussewitz, et al.Gynecologic Oncology Reports|April 17, 2023
Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case seriesCorinne A Calo, Monica D Levine, Morgan D Brown, et al.Gynecologic Oncology|June 15, 2023
The right time for change: A report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteriaPaulina J Haight, Courtney J Riedinger, Floor J Backes, et al.Journal of Minimally Invasive Gynecology|June 4, 2014
Training the next generation of robotic surgeons using guided mentorship: a randomized controlled trialMargaret I Liang, Georgia A McCann, Kellie S Rath, et al.Cancer|December 19, 2018
Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarkerFloor J Backes, Jennifer Haag, Casey M Cosgrove, et al.International Journal of Cancer|August 10, 2018
Functional characterization of recurrent FOXA2 mutations seen in endometrial cancersRobert Neff, Craig M Rush, Blair Smith, et al.Surgical Oncology|September 6, 2020
Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerationsDavid A Barrington, Ashley S Felix, Rieham Owda, et al.Pageof 17